Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

Sponsor
University Hospital, Bordeaux
Study ID
NCT07119970
Status
Recruiting
Apply to this trial

Conditions

  • Myeloproliferative Disorders
  • Myeloproliferative Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Additional blood sampling — BIOLOGICAL
    At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis

Study Details

Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.

Key Dates

First listed
Aug 13, 2025
Start date
Dec 9, 2025
Status verified
Jan 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
300 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Direct oral anticoagulants (DOACs)
  • Active Comparator: Aspirin

Primary Outcome Measure

Serum calprotectin concentration [ Time Frame: At T0 (inclusion) ]

Central Contacts

Related Studies